July 26, 2016 — Hematology researchers at The Children’s Hospital of Philadelphia (CHOP) have developed a novel ...

UltraSPECT Inc. announced recently that Robert Wood Johnson Physician Enterprise (RWJPE), a multi-specialty, community-based physician group in Central New Jersey, implemented UltraSPECT’s Xpress3.Cardiac solution at four of their sites.

CardioKinetix Inc. announced this week that 500 patients have received the company’s Parachute Ventricular Partitioning Device for heart failure. Patients have been treated in more than 15 countries, including patients in key international markets where the device is commercially available, and patients enrolled in PARACHUTE IV, the company’s U.S. pivotal trial under investigational device exemption (IDE).

A novel study has found a simple pre-operative echocardiographic measurement of the amount of torsion of the heart predicted outcomes of mitral valve surgery in some heart failure patients. The study was published in JACC: Basic to Translational Science.

At the end of June, experts from three different medical societies released a new guideline to help optimize lifetime management of patients with transposition of the great arteries, a congenital heart defect, both before and after surgical intervention.

Mitralign Inc. announced last week it has completed subject enrollment in the SCOUT early feasibility study in the United States.